National Health Research Institutes

Obi Pharma Inc.

National Taiwan University

Jmicron Technology Corp.

Shu-Yi Lin

Cheng-Der Tony Yu

Chung-Shi Yang

Yih-Huang Hsieh

Peiwen Yu

Shiuh-Jer Huang

Guang-Ling He

I-Ju Chen

Yeu-Kuang Hwu

Cheng-Chi Wang

Leu-Wei Lo

Wei-Han Lee

Yin-Cheng Hsieh

Chin-Sheng Chao

Ming-Tain Lai

Wei-Chien Tang

Kai-Lung Cheng

Yuan-Chu Yu

Kuo-Pao Lai

A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The 'R-form' compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the 'S-form' compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.

Methods of making high enantioselective secondary alcohols

The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

Immunogenic/therapeutic glycan compositions and uses thereof

The invention relates to linkers and methods for generating arrays with linkers. The invention also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for epitope identification, drug discovery and as analytical tools. The invention provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing cancer.

Glycan arrays and method of use

A caged platinum nanocluster complex is disclosed. The complex comprises (a) an amine-terminated dendrimer; and (b) a platinum nanocluster comprising platinum oxides, the platinum nanocluster being confined inside of the amine-terminated dendrimer. The complex exhibits cytotoxicity to cancer cells. A double-caged platinum nanocluster complex is also disclosed, which comprises polyethylene glycol (PEG) coated on the surface of a dendrimer caged platinum nanocluster complex. The double-caged caged platinum nanocluster complex comprises pH-sensitive bonds on the surface thereof. Also disclosed are methods of preparing and using the same.

Caged platinum nanoclusters for anticancer chemotherapeutics

A method of synthesizing a random copolymer of polyethyleneimine and polyethylene glycol, comprising exposing ethanolamine in a solution to electromagnetic radiation for a sufficient time to polymerize the ethanolamine (OHCHCHNH) and thereby resulting in formation of the randome copolymer comprising polyethyleneimine and poly(ethylene glycol), wherein the polyethyleneimine comprises ethyleneimine (&#x2014;CHCHNH&#x2014;) unit and the polyethylene glycol comprises ethylene glycol (&#x2014;CHCHO&#x2014;) unit, and the polyethylenimine of the random copolymer has a substantially linear backbone.

Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery

The present invention provides a method for estimating a capacity usage status of a storage unit, where the storage unit includes a plurality of sectors. The method includes: estimating capacity usage statuses of a portion of sectors; and utilizing a controller to estimate the capacity usage status of the storage unit according to the estimated capacity usage statuses of the portion of sectors in a situation of not estimating capacity usage statuses of all of the sectors of the storage unit.

Method for estimating capacity usage status of storage unit, associated memory device and controller thereof

A quantum dot (QD) conjugate comprises a QD and a ligand conjugated with the QD, in which the ligand has at least one thiol and at least one other functional group. The QD conjugate may further comprise a bioactive agent covalently coupled to the ligand to form a bioactive agent-tagged QD conjugate. A method for preparing a QD conjugate comprises the steps of: (1) providing a solution comprising a QD encapsulated within a dendrimer; (2) adding into the solution a ligand; and (3) allowing an exchange between the ligand and the dendrimer for the QD to obtain a ligand-QD conjugate, in which the ligand is covalently conjugated to the surface of the QD. The method may further comprise the step of coupling the ligand-QD conjugate to a bioactive agent to obtain a bioactive agent-tagged ligand-QD conjugate.

Method for making a ligand-quantum dot conjugate

The invention provides a novel control method combining fuzzy logic control with gain auto-tuning sliding mode control. A control error signal e(t) from the detection mechanism and an error change signal ce(t) are combined together as a sliding variable s(t)=ce(t)+&#x3bb;e(t) and used as the fuzzy input control variable. Using the control method, 2D fuzzy control rule is simplified into 1D fuzzy control rule through the sliding variable definition for enhancing the efficiency of computation and saving computation resources. Accordingly, both the quick transient response and steady state precision positioning can be achieved. The present method can overcome the disadvantages of current controller, which can not reach the desired transient and steady state responses simultaneously.

Control method combining fuzzy logic control with sliding mode control for ideal dynamic responses

A polishing apparatus and a pad replacing method thereof are provided. The polishing apparatus includes a first clamping element, a second clamping element and a polishing head. The first clamping element includes a first upper clamper and a first lower clamper for clamping a first area of a first polishing pad. The second clamping element includes a second upper clamper and a second lower clamper for clamping a second area of the first polishing pad, the first area and the second area are opposite to each other. When the first polishing pad will be disconnected from the bottom surface of the polishing head and replaced by a second polishing pad, the first clamping element and the second clamping element are released from the first polishing pad.

Growing community of inventors

Taipei, Taiwan

Shu-Yi Lin